Home

The Melbourne Protein Characterisation (MPC), located within the Bio21 Institute, is a diverse facility for protein production and investigating protein quality control, molecular interactions and structural analysis. The Platform incorporates part of the Australian Cancer Research Foundation (link is external)(ACRF) Facility for Innovative Cancer Drug Discovery and forms part of the drug discovery pipeline that connects the Bio21 platforms together. MPC has 4 facilities which are Protein Production, Protein Interaction, X-ray Diffraction and Bio21-WEHI Crystallisation Facility. 

The MPC capabilities include: 

Protein Production & Peptide Synthesis

  • Insect and mammalian cells tissue culture

  • Microwave peptide synthesizer

X-ray Diffraction

  • Analysis of structure for small molecules and proteins

Protein Interaction

  • Study of molecular binding and interactions

  • Analysis of oligomerisation and association states

  • Determination of protein size, shape and secondary structure

  • Study of heterogeneity and aggregation

  • Analysis of fluorescence and UV absorbance

  • Detection of small molecule binding

 

Crystallisation

  • Screening of initial crystallisation conditions

  • Lipid cubic phase crystallisation

  • Optimisation of Hit crystallisation conditions

  • Crystal plate imaging

 

 

 

Platform is open-access, offering services to both academic and industry users, including training by platform technology specialists and fee-for-service options.

 
For any enquiries, please contact us on  bio21-mpc@lists.unimelb.edu.au(link sends e-mail). 

 

Latest News Title

News

  • SEC-MALS arrives at Bio21 Melbourne Protein Characterisation

    31 January 2020
  • Biacore S200 arrives at Bio21

    The Biacore S200 arrived at Bio21 Institute on Monday, 17 June 2019. This instrument, that is used to characterize molecular interactions, is one of a suite of instruments that has been funded by the Australian Cancer Research Foundation as part of the ACRF Facility for Innovative Cancer Drug Discovery. It is currently being installed and will be available soon.
  • Media Release: ACRF cancer research facility to harness structural biology for cancer drug discovery

    28 November 2018

    The Australian Cancer Research Foundation (ACRF) will provide $2 million to fund the creation of the ACRF Facility for Innovative Cancer Drug Discovery at the Bio21 Institute, University of Melbourne.

    The chief investigators, Professor Michael Parker and Dr David Ascher of Bio21, Professor Rick Pearson of the Peter MacCallum Cancer Centre and Professor John Silke of the Walter and Eliza Hall Institute, represent some of Victoria’s major cancer research institutions.

Latest News Link

More News 

Homepage Events Title

Events

Homepage Events Link

More Events